Lawrence H. Fong

MD

Genitourinary oncologist
Cancer immunotherapist and laboratory head

Dr. Lawrence Fong is a medical oncologist who specializes in immunotherapy to care for cancer patients with an emphasis on genitourinary cancers (those involving the genital or urinary organs).

A physician-scientist, Fong studies new immunotherapies for cancer. He is nationally known for his work on cancer vaccines and immune checkpoint inhibitors (drugs that prevent an immune system response that can stop cancer cells from being destroyed). He has helped conduct numerous clinical trials (evaluations of potential new treatments using human volunteers) and is the principal investigator on multiple research projects that have received grants from federal agencies and private foundations. As the leader of UCSF's cancer immunotherapy program, he helps to develop new treatments through early-phase clinical trials of novel immunotherapies. His laboratory focuses on understanding why current treatments work in some patients but not others.

Fong earned his medical degree at Stanford University. He completed a residency in internal medicine at the University of Washington. He completed an oncology fellowship at Stanford Medicine.

Fong joined the UCSF faculty in 2001 and is the Efim Guzik Distinguished Professor in Cancer Biology. He has published more than 100 peer-reviewed scientific articles and multiple book chapters. He has lectured nationally and internationally on cancer immunotherapy.

  • Education

    Stanford University School of Medicine, MD, 1992

  • Residencies

    University of Washington, Internal Medicine, 1994

  • Fellowships

    Stanford Medicine, Oncology, 1997

  • Board Certifications

    Medical Oncology, American Board of Internal Medicine

  • Academic Title

    Professor

My goal is to improve treatment of cancer through immunotherapy.

Conditions I specialize in

Clinics I work with

View map

Cancer Immunotherapy Clinic

Bakar Precision Cancer Medicine Building

1825 Fourth St., Fifth Floor
San Francisco, CA 94158

(415) 353-2421

Genitourinary Medical Oncology Clinic

Bakar Precision Cancer Medicine Building

1825 Fourth St., Sixth Floor
San Francisco, CA 94158

(415) 476-4616
M-F, 8 a.m. - 5 p.m.

Prostate Cancer Center

Bakar Precision Cancer Medicine Building

1825 Fourth St., Sixth Floor
San Francisco, CA 94158

M-F, 8 a.m. - 5 p.m.

My reviews

5.0

Overall Experience
84 Ratings
Explained things in a way that was easy to understand
84 Ratings
Did the doctor pay attention to your concerns
84 Ratings
Gave easy to understand instructions about taking care of health problems or concerns
80 Ratings
Knew the important information about your medical history
84 Ratings
The provider showed respect for what you had to say
83 Ratings
The provider spent enough time with me
83 Ratings
Read all reviews About our process

Selected research

See all research
Decorative Caduceus

CPI-006 Alone and in Combination With Ciforadenant and With Pembrolizumab for Patients With Adv...

Recruiting

Decorative Caduceus

A Study of TNB-585 in Subjects With Metastatic Castrate-Resistant Prostate Carcinoma

Recruiting

Decorative Caduceus

Adenosine Receptor Antagonist Combination Therapy for Metastatic Castrate Resistant Prostate Ca...

ORR defined as the composite proportion of participants with a Prostate Specific Antigen (PSA) and/or radiographic complete response (CR) and partial response (PR) determined by the investigator according to the Prostate Cancer Wo...

Recruiting

Decorative Caduceus

Platform Study for Prostate Researching Translational Endpoints Correlated to Response to Infor...

Recruiting

Decorative Caduceus

Pembrolizumab +/- SD-101 in Hormone-Naïve Oligometastatic Prostate Cancer With RT and iADT

Only patients in cohort 2, who achieve testosterone recovery to non-castrate levels (>150 ng/dL) at 15 months, will be analyzed for the primary endpoint. The rate of PSA < nadir + 2 ng/mL at 15 months from the start of radiotherap...

Recruiting

Decorative Caduceus

Neoadjuvant Atezolizumab-Based Combination Therapy in Men With Localized Prostate Cancer Prior ...

A positive response is defined as a ≥40% increase in the number of infiltrating cluster of differentiation 3 (CD3) + T cells between the pre-treatment biopsy at baseline and the post-treatment RP specimen. Thus, a negative respons...

Recruiting

Decorative Caduceus

Study of HPN424 in Patients With Advanced Prostate Cancer

In Part 1, measure incidence of dose limiting toxicities measured by adverse events and serious adverse events by dose level.

Recruiting

Contact me

Providers on my team

Share